Skip to Main Content

Paper Details

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat
76
2020
Author NameAffiliation
Dennis J SlamonDavid Geffen School of Medicine, University of California Los Angeles
  • 1 - 1

Datasets

Release 1.2